Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes

Cancer Gene Therapy

Volumn 5, Issue 2, 1998, Pages 119-126

  Stopeck, Alison T ^a   Hersh, Evan M ^a   Brailey, Jacqueline L ^a   Clark, Paul R ^b   Norman, Jon ^b   Parker, Suezanne E ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b VICAL INC   (United States)

Author keywords

Cationic lipids; Gene transfer; Gene modified tumor cells; Transfection

Indexed keywords

BETA GALACTOSIDASE; CANCER VACCINE; DNA; INTERLEUKIN 2; LIPID;

ARTICLE; AVIAN SARCOMA VIRUS; BIOSYNTHESIS; CELL CULTURE; CYTOMEGALOVIRUS; ESCHERICHIA COLI; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOKINE ACTIVATED KILLER CELL; NEOPLASM; PATHOLOGY; PLASMID; PROMOTER REGION;

AVIAN SARCOMA VIRUSES; BETA-GALACTOSIDASE; CANCER VACCINES; CYTOMEGALOVIRUS; DNA; ESCHERICHIA COLI; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIPIDS; NEOPLASMS; PLASMIDS; PROMOTER REGIONS (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032017880     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bruton JK, Koeller JM. Recombinant Interleukin-2. Pharmacotherapy. 1994;14:635-656.
2. Smith KA. Interleukin-2. Sci Am. 1990;March:50-57.
3. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
4. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 1994;54:3516-3520.
5. Cavallo F, DiPierro F, Giovarelli M, et al. Protective and curative potential of vaccination with interleukin-2 genetransfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 1993;53:5067-5070.
6. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-905.
7. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474-485.
8. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1987;7:7-20.
9. Qin H, Chatterjee SK. Recombinant vaccinia expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther. 1996;3:163-167.
10. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60: 397-403.
11. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
12. Osanto S, Brouwenstijn N, Vaessen N, et al. Immunization with interleukin-2 transfected melanoma cells: a phase I-II study in patients with metastatic melanoma. Hum Gene Ther. 1993;4:323-330.
13. Gansbacher B, Houghton A, Livingston P, et al. A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther. 1992;3:677-690.
14. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol. 1995;25:1137-1140.
15. Cassileth PA, Podack E, Sridhar K, et al. Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum Gene Ther. 1995;6:369-383.
16. Parker SE, Khatibi S, Margalith M, et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther. 1996;3:175-185.
17. Norn NA, Meek JA, Budahazi G, et al. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther. 1995;6:565-573.
18. Couffinhal T, Kearney M, Sullivan A, et al. Histochemical staining following LacZ gene transfer underestimates transfection efficiency. Hum Gene Ther. 1997;8:929-934.
19. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin. 1996;46:225-244.
20. Porgador A, Gansbacher B, Bannerji R, et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-inserted tumor cells. Int J Cancer. 1993;53:471-477.
21. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
22. Cignetti A, Guarini A, Carbone A, et al. Transduction of the IL-2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL-2 receptor expression. J Natl Cancer Inst. 1994;86:785-792.
23. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of Interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
24. Smith TA, Mehaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 1993;5:397-402.
25. Lemarchand P, Jones M, Yamada I, et al. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 1993;72:1132-1138.
26. Blaese M, Blankenstein T, Brenner M, et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995;2:291-297.
27. Akporiaye ET, Schluter S, Harris DT, et al. Expression of intratumorally injected HLA-B7 gene: results from a phase I clinical trial. Proc Am Assoc Cancer Res. 1995;36:220. Abstract.
28. Stopeck A, Hersh E, Warneke J, et al. Results of a phase I study of direct gene transfer of interleukin-2 formulated with cationic lipid vector, leuvectin, in patients with metastatic solid tumors. Proc Am Soc Clin Oncol. 1996;15:235. Abstract.
29. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997;15:341-349.
30. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med. 1996;2:1090-1095.
31. Hughes BW, Wells AH, Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 1995;55:3339-3345.
32. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994;54:5258-5261.
33. Vile RG, Hart IR. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann Oncol. 1994;5:59-65.
34. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Ther. 1995;2:710-722.